These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31931437)

  • 21. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.
    Wang F; Zhao YK; Li M; Zhu Z; Zhang X
    Cutan Ocul Toxicol; 2017 Dec; 36(4):370-376. PubMed ID: 28423957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
    Li R; Zhou Q; Ou S; Wang Y; Li Y; Xia L; Pan S
    Epilepsy Res; 2020 Oct; 166():106408. PubMed ID: 32679487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
    Kanemura H; Sano F; Aihara M
    Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia.
    Cvetkovska E; Kuzmanovski I; Babunovska M; Boshkovski B; Aleksovska K; Trencevska GK
    Clin Neuropharmacol; 2018; 41(6):218-221. PubMed ID: 30234559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
    Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
    J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis.
    Alfares I; Javaid MS; Chen Z; Anderson A; Antonic-Baker A; Kwan P
    CNS Drugs; 2021 Feb; 35(2):161-176. PubMed ID: 33580477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam.
    Lim JA; Jamil A; Ramli NA; Johar FM; Nor M
    Am J Health Syst Pharm; 2024 Jan; 81(3):e69-e72. PubMed ID: 37864830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
    Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
    Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levetiracetam in toxic seizures.
    Lee T; Warrick BJ; Sarangarm P; Alunday RL; Bussmann S; Smolinske SC; Seifert SA
    Clin Toxicol (Phila); 2018 Mar; 56(3):175-181. PubMed ID: 28753046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.
    French J; Edrich P; Cramer JA
    Epilepsy Res; 2001 Nov; 47(1-2):77-90. PubMed ID: 11673023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
    Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome.
    Gómez-Zorrilla S; Ferraz AV; Pedrós C; Lemus M; Peña C
    Ann Pharmacother; 2012; 46(7-8):e20. PubMed ID: 22764327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam?
    Bosman T; Vonck K; Claeys P; Van Vlierberghe H; De Clercq M; De Reuck J; Boon P
    Seizure; 2004 Mar; 13(2):76-81. PubMed ID: 15129834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid and thyroid hormone levels in children with epilepsy treated with levetiracetam or carbamazepine: A prospective observational study.
    Nishiyama M; Takami Y; Ishida Y; Tomioka K; Tanaka T; Nagase H; Nakagawa T; Tokumoto S; Yamaguchi H; Toyoshima D; Maruyama A; Nozu K; Nishimura N; Iijima K
    Epilepsy Behav; 2019 Jan; 90():15-19. PubMed ID: 30500483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis.
    Lattanzi S; Trinka E; Del Giovane C; Nardone R; Silvestrini M; Brigo F
    Epilepsia; 2019 Nov; 60(11):2245-2254. PubMed ID: 31608438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.
    Campbell C; McCormack M; Patel S; Stapleton C; Bobbili D; Krause R; Depondt C; Sills GJ; Koeleman BP; Striano P; Zara F; Sander JW; Lerche H; Kunz WS; Stefansson K; Stefansson H; Doherty CP; Heinzen EL; Scheffer IE; Goldstein DB; O'Brien T; Cotter D; Berkovic SF; ; Sisodiya SM; Delanty N; Cavalleri GL
    Epilepsia; 2022 Jun; 63(6):1563-1570. PubMed ID: 35298028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: A sensitive monitoring biomarker in patients with epilepsy.
    Harby SA; Nassra RA; Mekky JF; Ali SM; Ismail CA
    Seizure; 2020 May; 78():71-77. PubMed ID: 32213443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous adverse drug reactions in Indian population: A systematic review.
    Patel TK; Thakkar SH; Sharma D
    Indian Dermatol Online J; 2014 Dec; 5(Suppl 2):S76-86. PubMed ID: 25593813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.